In a noteworthy session last week at the American Heart Association conference, researchers presented evidence that the obesity drug semaglutide (Wegovy), a glucagon-like peptide-1 receptor agonist, demonstrated benefits beyond weight loss by reducing the overall rate of major cardiovascular concerns by 20%. In the results of double-blind trial, which appear in the New England Journal of Medicine, they found a reduced incidence of heart attacks, cardiovascular-related deaths, and strokes. Semaglutide notably reduced heart attacks by …
Read More